ClinicalTrials.gg
Not yet recruitingNCT07945756HBM-GCSUpdated Nov 18, 2026

Development of a Gastric Cancer Screening Intervention for H. Pylori Carriers Based on the Health Belief Model

An interventional study of Health Belief Model-based screening promotion intervention and Usual Care in Gastric Cancer (GC), sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in China. Open to participants aged 45 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Screening

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
45 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Stomach Neoplasms by Chinese University of Hong Kong — 10 open to participants now, 10 under way, 1 of them phase 3. Stomach Neoplasms · Chinese University of Hong Kong.

Planned enrollment
7th of 14
70 · median 60
Started
2026
the only one that year
No phase
6 of 18
4 open now
Registered
18th of 18
by date

Among the 18 studies in Stomach Neoplasms by Chinese University of Hong Kong, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 18th registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 18 studies in Stomach Neoplasms by Chinese University of Hong Kong are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 45 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stomach Neoplasms by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Gastric cancer (GC) remains a major global public health challenge. It often causes no obvious symptoms in the early stage, so most patients are diagnosed at an advanced stage. This highlights the importance of gastric cancer screening among high-risk populations to achieve early detection and improve survival outcomes. People infected with Helicobacter pylori (Hp) are at high risk of gastric cancer. Hp is one of the most common bacterial infections worldwide. It initiates carcinogenesis by triggering chronic atrophic gastritis and intestinal metaplasia, known as the Correa cascade. However, the acceptance of gastric cancer screening among Hp-infected individuals is still unsatisfactory. To our knowledge, there are few theory-based interventions designed to help Hp-infected people make decisions about gastric cancer screening and increase screening uptake. Therefore, based on our previous systematic review, this study aims to develop a health promotion program to improve gastric cancer screening participation among Hp-infected individuals in mainland China. Participants in the intervention group will receive a comprehensive health promotion program, including a 30-minute health education session. They will receive a 15-minute telephone follow-up with gastric cancer screening information in week 2, and additional 10-minute telephone follow-ups at weeks 2, 4, and 6 to help participants identify and overcome barriers to gastric cancer screening. Participants in the control group will receive routine care. Data on gastric cancer screening participation will be collected at the end of the intervention. Findings from this study will be valuable for gastric cancer prevention among people with Hp infection.

Read the detailed description

Participants in the intervention group will receive the following multi-session health promotion intervention. The details are as follows.

Screening benefit construction (30 min). In the first week, education will be delivered through face-to-face for the following information:

(1) Hp infection and increased gastric cancer risk; (2) gastric cancer screening recommendations regarding eligibility, available screening tests, and recommended screening intervals; (3) pros/advantages of undergoing gastric cancer screening; (4) cons/disadvantages or uncertainties of undergoing gastric cancer screening; (5) implications of positive screening results; and (6) health costs and service information. The educational material will be presented in a self-made manual, which will be explained and distributed to each participant.

Screening barrier navigation (15 min). It will be conducted in the second week by telephone. The nurse counsellor will help participants resolve individual barriers related to gastric cancer screening. The tailored content includes:

(1) Q\&A about gastroscopy screening; (2) gastroscopy appointment procedure; (3) hospital and transportation information; (4) medical insurance consultation; (5) precautions for the examination.

Screening self-efficacy reinforcement (10 min each). At the fourth and sixth weeks, the nurse counsellor will work with participants through a telephone-based way (with WeChat as an auxiliary tool) to strengthen confidence in completing gastric cancer screening, in which participants will: (1) track the progress of screening arrangements; (2) receive home health guidance while waiting for the screening examination.

Participants in the control group will receive routine health care for Hp infection without this theory-based gastric cancer screening promotion program.

03

Conditions studied

  • Gastric Cancer (GC)

Browse trials for

Keywords

  • Gastric Cancer
  • Helicobacter pylori
  • Screening
  • Early detection
  • Gastroscopy
  • Intervention
  • Health promotion
04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 45 and 74 years.
  2. Diagnosed with *Helicobacter pylori* infection confirmed by urea breath test (UBT), serological antibody test, or stool antigen test.
  3. Have adequate communication, reading, and comprehension ability.
  4. Provide , voluntarily participate in the study, and cooperate with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • 1. Previously diagnosed with gastric cancer or other advanced malignant tumors. 2. Cognitive impairment, severe hepatic or renal insufficiency, psychiatric disorders, or severe physical illness that prevents cooperation with the interview.

    3. Pregnant or breastfeeding women.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Experimental: Health Belief Model-based intervention group

    Provide education, tailored information, barrier counseling, and decision support regarding gastric cancer screening for Helicobacter pylori-infected individuals.

    Other: Health Belief Model-based screening promotion intervention

  • Other
    Control group

    Usual care provided by the hospital, including one-page written education material on gastroscopy.

    Other: Usual Care

Interventions

  • OtherHealth Belief Model-based screening promotion intervention

    Provide health education, tailored information, barrier counseling and follow-up regarding gastric cancer screening for Helicobacter pylori-infected individuals.

  • OtherUsual Care

    Usual care provided by the hospital, including one-page written education material on gastroscopy.

06

What researchers measure

Primary outcomes

  1. Gastric cancer screening intention

    Participants' behavioral tendency and psychological readiness to actively seek and undergo gastroscopy within the next 5 years.

    Time frame: Immediately and 6 weeks after intervention

  2. Gastroscopy completion rate

    An objective outcome is defined as the number of participants who complete gastroscopy after intervention. The gastroscopy completion rates among Helicobacter pylori-infected participants in the two groups will be compared, serving as the key quantitative indicator to evaluate whether the intervention improves actual screening behavior.

    Time frame: 6 weeks after intervention

Secondary outcomes

  1. Gastric cancer screening knowledge score

    Assessed with knowledge items from Huang et al. (2022). The scale measures participants' knowledge of gastric cancer risk factors and warning symptoms, consisting of 24 items on risk factors and 14 items on warning symptoms.

    Time frame: Immediately and 6 weeks after intervention

  2. Total score of the Health Belief Model (HBM) questionnaire for gastric cancer screening

    This subscale was developed based on the five-dimensional HBM framework proposed by Becker (1974), including perceived susceptibility to gastric cancer (3 items), perceived severity (3 items), perceived benefits of gastric cancer screening (2 items), perceived barriers to screening (5 items), and cues to action (3 items). The total score of the five dimensions is calculated.

    Time frame: Immediately and 6 weeks after intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 357 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 66. This study's planned 4 months is below that.

Counting every sponsor, half of 368 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945756
Responsible party
LI Caixia (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Mengyao Gao, MN
Contact
15870682367@163.com
(86)15870682367
Caixia Li, PhD
Contact
licx23@mail.sysu.edu.cn
(86) 19867712062
Mengyao Gao, MN
principal investigator · Kiang Wu Nursing College of Macau(KWNC)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion